Biopharmaceutical and drug delivery technologies company Nektar Therapeutics has been declining for seven months losing some 80% in stock price. The decline is much correlated with the delay in launching insulin inhaled drug Exubera managed by marketing partner Pfizer. However, a recent breakout of the downtrend occurring three trading sessions ago may signal the beginning of a trend-reversal.
No comments:
Post a Comment